Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

Article activity feed

1. Version published to 10.1016/j.cell.2021.02.035

   Apr 1, 2021
2. 

   ScreenIT

   Mar 1, 2021

   SciScore for 10.1101/2020.10.07.328302: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	Consent: IRCCS - Lazzaro Spallanzani Rome (IT) and Azienda Ospedaliera Universitaria Senese, Siena (IT) that provided samples from SARS-CoV-2 convalescent donors who gave their written consent. IRB: The study was approved by local ethics committees (Parere 18_2020 in Rome and Parere 17065 in Siena) and conducted according to good clinical practice in accordance with the declaration of Helsinki (European Council 2001, US Code of Federal Regulations, ICH 1997).
   Randomization	This study was unblinded and not randomized.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   …

   SciScore for 10.1101/2020.10.07.328302: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	Consent: IRCCS - Lazzaro Spallanzani Rome (IT) and Azienda Ospedaliera Universitaria Senese, Siena (IT) that provided samples from SARS-CoV-2 convalescent donors who gave their written consent. IRB: The study was approved by local ethics committees (Parere 18_2020 in Rome and Parere 17065 in Siena) and conducted according to good clinical practice in accordance with the declaration of Helsinki (European Council 2001, US Code of Federal Regulations, ICH 1997).
   Randomization	This study was unblinded and not randomized.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Blood samples were screened for SARS-CoV-2 RNA and for antibodies against HIV, HBV and HCV.	antibodies against HIV suggested: None HCV suggested: None
   ELISA assay with S1 and S2 subunits of SARS-CoV-2 S-protein: The presence of S1- and S2-binding antibodies in culture supernatants of monoclonal S-protein-specific memory B cells was assessed by means of an ELISA assay implemented with the use of a commercial kit (ELISA Starter Accessory Kit, Catalogue No. E101; Bethyl Laboratories).	S2-binding suggested: None
   After an incubation of 1 h at 37°C, plates were washed and incubated with 25 μl/well secondary antibody (horseradish peroxidase (HRP)-conjugated goat anti-human IgG-Fc Fragment polyclonal antibody, diluted 1:10,000 in blocking buffer, Catalogue No. A80-104P; (Bethyl Laboratories) for 1 h at 37°C.	anti-human IgG-Fc suggested: (Bethyl Cat# A80-104P, RRID:AB_67064)
   25 μL/well of alkaline phosphatase-conjugated goat anti-human IgG (Sigma-Aldrich) and IgA (Jackson Immuno Research) were used as secondary antibodies.	alkaline phosphatase-conjugated goat anti-human IgG suggested: (Jackson ImmunoResearch Labs Cat# 109-055-190, RRID:AB_2888997)
   PNPP (p-nitrophenyl phosphate) (Thermo Fisher) was used as soluble substrate to detect SARS-CoV-2 S-protein specific monoclonal antibodies and the final reaction was measured by using the Varioskan Lux Reader (Thermo Fisher Scientific) at a wavelength of 405 nm.	( p-nitrophenyl phosphate ) suggested: None p-nitrophenyl phosphate suggested: None
   Affinity evaluation of SARS-CoV-2 neutralizing antibodies: Anti-Human IgG Polyclonal Antibody (Southern Biotech 2040-01) was immobilized via amine group on two flow cells of a CM5 sensor chip.	SARS-CoV-2 neutralizing antibodies: Anti-Human IgG Polyclonal Antibody suggested: None
   Following the capture of each mAb by the immobilized anti-human IgG antibody, different concentrations of SPIKE protein (20 μg/ml, 10 μg/ml, 5 μg/ml, 2.5 μg/ml and 1 μg/ml in HBS-EP+) were injected over both the blank flow cell and the flow cell containing the captured mAb for 180 sec at a flow rate of 80 μl/min.	anti-human IgG suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   For titration and neutralization tests of SARS-CoV-2, Vero E6 were seeded in 96-well plates (Sarstedt) at a density of 1,5×104 cells/well the day before the assay.	Vero E6 suggested: None
   Software and Algorithms
   Sentences	Resources
   The protein was purified from filtered cell supernatants using NiNTA resin (GE Healtcare #11-0004-58)	GE Healtcare suggested: None
   Results were analyzed by FlowJo (version 10)	FlowJo suggested: (FlowJo, RRID:SCR_008520)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2020.10.07.328302 on bioRxiv

   Oct 7, 2020